Special instructions for executing this Antibody licenseAntibody License Agreement • November 19th, 2022 • Illinois
This Ready-to-Sign license agreement (RtS) includes non-negotiable, standard terms and conditions that are designed to enable rapid licensing. In order to enter into an RtS license agreement and to receive rights to use the intellectual property described in the license, please follow the instructions outlined below.
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. ANTIBODY LICENSE AGREEMENTAntibody License Agreement • July 26th, 2022 • Avista Public Acquisition Corp. II • Services-commercial physical & biological research • New York
This Antibody License Agreement (“Agreement”) is entered into effective December 20, 2012 (“Effective Date”) by Open Monoclonal Technologies, Inc. (“OMT”), a Delaware corporation having its principal place of business at 2747 Ross Road, Suite A, Palo Alto, CA 94303 and CNA Development LLC (“Licensee”), a Delaware limited liability company, having its principal place of business at [***].
1 EXHIBIT 10.8 [CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION] ANTIBODY LICENSE AGREEMENT THIS AGREEMENT, dated September 22, 1995, is entered into by and...Antibody License Agreement • February 10th, 1997 • Biosite Diagnostics Inc • In vitro & in vivo diagnostic substances
BETWEENAntibody License Agreement • June 5th, 2001 • Cambridge Antibody Technology Group PLC • Services-commercial physical & biological research • New York
